# A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Clinical trial · Janssen Research & Development, LLC

- Archive id: nct:NCT02497287
- Published: 2015-07-14
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02497287
- Source URL: https://clinicaltrials.gov/study/NCT02497287
- Provenance: clinicaltrials

## Abstract

The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: SUSTAIN-2
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 802
- sponsor: Janssen Research & Development, LLC
- conditions: Treatment-resistant Depression
- interventions: DRUG: Esketamine (Intranasal Spray); DRUG: Duloxetine (Oral Antidepressant); DRUG: Escitalopram (Oral Antidepressant); DRUG: Sertraline (Oral Antidepressant); DRUG: Venlafaxine Extended Release (XR) (Oral Antidepressant)
- start date: 2015-09-30
- start date type: ACTUAL
- primary completion date: 2017-10-28
- has results: true
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Novel Psychiatric Therapeutics](https://space-kitty.com/topics/psychiatric-therapeutics)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.